Haemonetics Acquires Vivasure as EQT Life Sciences Concludes Long-Term Investment

Haemonetics Acquires Vivasure as EQT Life Sciences Concludes Long-Term Investment

(IN BRIEF) EQT Life Sciences has exited its investment in Vivasure Medical following the sale of the Irish medical technology company to Haemonetics. Backed by EQT since 2016, Vivasure developed the PerQseal® Elite system, a bioabsorbable, sutureless solution for large-bore vessel closure. The transaction includes EUR 100 million upfront and up to EUR 85 million in additional milestone-based consideration, marking a successful conclusion to EQT’s long-term support of the company’s clinical and regulatory journey.

(PRESS RELEASE) STOCKHOLM, 12-Jan-2026 — /EuropaWire/ — EQT Life Sciences has agreed to exit its investment in Vivasure Medical following the sale of the Galway-based medical technology company to Haemonetics Corporation, a global provider of solutions aimed at improving patient outcomes. The transaction marks the culmination of nearly a decade of support by EQT Life Sciences, from late-stage clinical development through to regulatory progress.

Vivasure Medical is the developer of the PerQseal® Elite system, a next-generation, sutureless vessel closure solution designed for large-bore arterial and venous access sites. The technology uses a bioabsorbable patch deployed from within the vessel, offering a fully absorbable alternative for structural heart and endovascular procedures. In 2025, Vivasure submitted a Premarket Approval application to the U.S. Food and Drug Administration and secured CE Mark approval in Europe for both arterial and venous indications.

EQT Life Sciences, formerly operating as LSP, first invested in Vivasure in 2016 through the LSP Health Economics Fund, leading the company’s Series C financing. Over the course of its investment, EQT actively supported Vivasure’s clinical strategy, regulatory pathway and organizational development. From 2016 to 2025, EQT Partner Anne Portwich served on Vivasure’s board, contributing to the company’s advancement toward commercialization.

Under the terms of the agreement, Haemonetics will acquire Vivasure for an upfront cash consideration of EUR 100 million, with the potential for up to an additional EUR 85 million in milestone-based payments tied to commercial performance and other predefined objectives. EQT’s fund will receive proceeds corresponding to its minority ownership stake.

Haemonetics plans to integrate Vivasure’s technology into its interventional portfolio, strengthening its position in the growing large-bore closure market and expanding its capabilities in structural heart and endovascular interventions. The acquisition is expected to accelerate the global availability of PerQseal Elite, leveraging Haemonetics’ commercial scale and operational infrastructure.

About EQT Life Sciences
EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences aims to back the smartest inventors who have ideas that could truly make a difference for patients

More info: www.eqtgroup.com/private-capital/eqt-life-sciences

About Vivasure Medical Limited
Based in Galway, Ireland, Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery. Vivasure operates a fully integrated R&D and ISO 13485 certified manufacturing facility. PerQseal and PerQseal Elite are not available for sale in the United States.

For more information, please visit www.vivasuremedical.com

About Haemonetics
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components.

To learn more about Haemonetics, visit www.haemonetics.com

Media Contact:

EQT Press Office, press@eqtpartners.com

SOURCE: EQT